ROTH Capital Partners acts as Sole Book-Running Manager
for Myomo, Inc. (NYSE American: MYO)
in its $15 Million Follow-On

   

For more information please contact:
 
Investment Banking
Eric B. Cheng
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1901
echeng@roth.com
 
James Antonopoulos
Managing Director
Co-Head of Healthcare
Investment Banking
(646) 358-1906
jantonopoulos@roth.com
 
Aparna Beeram
Vice President
(646) 358-1912
abeeram@roth.com
 
Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703
agurewitz@roth.com
 
Nazan Akdeniz
Senior Vice President
(949) 720-5740
nakdeniz@roth.com
 
Lou Ellis
Senior Vice President
(949) 720-5739
lellis@roth.com

Transaction Information
Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, has closed an underwritten public offering of 2,143,000 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 2,143,000 shares of common stock.

Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one investor warrant to purchase one share of common stock at a combined offering price of $7.00, resulting in the gross proceeds for Myomo of approximately $15.0 million.

The investor warrants have an exercise price of $7.50 per share, are immediately exercisable and will expire five years from the date of issuance. Myomo has granted the underwriters a 45-day option to purchase an additional 321,450 shares of common stock, and/or investor warrants to purchase up to 321,450 shares of common stock, in any combinations thereof, at the public offering price per security, less the underwriting discounts and commission.

ROTH Capital Partners acted as sole book-running manager for the offering.

About Myomo
Myomo, Inc. is a wearable medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line.  For more information, please visit https://myomo.com. (Source: Company Press Release | 02/11/20)

About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

Date of Announcement: 02/14/20

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2020.